BASF completes Pronova acquisition


Expanding its omega-3 business in the Nutrition & Health division

BASF has completed the acquisition of Pronova BioPharma, a Norwegian specialst in the production of omega-3 fatty acids, which are used to treat cardiovascular diseases.

The transaction closed with the payment of the offer price of NOK13.50 per share to Pronova shareholders, valuing Pronova at approximately €684m. At the same time, the tendered shares were transferred to BASF, which now holds 98.19% of Pronova.

BASF is setting up a compulsory acquisition process (squeeze out) to acquire the remaining shares belonging to Pronova’s minority shareholders.

Sign up for your free email newsletter

The German chemicals giant will integrate Pronova into its Nutrition & Health division, where it will become a key part of BASF’s omega-3 business.